In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: April 2011

Executive Summary

Meda paid $420 million in cash for exclusive worldwide rights to Novartis' dermatitis cream Elidel. J&J's acquisition of orthopedic device company Synthes topped the acquisition list at $21.7 billion. The $1.6 billion in biopharma financing was outshone by Royalty Pharma's $487 million purchase of Cubicin and Lexiscan royalties. Similarly the one outlier device transaction - DJO's $300 million notes offering - represented 64% of the $471 million in device fundraising.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV003655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel